Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Q1 2026 Earnings Presentation
32 slides from Abcellera Biologics's earnings presentation, May 11, 2026
Slide 1: AbCellera Corporate Overview
AbCellera Corporate Overview COPYRIGHT © ABCELLERA January 14, 2026
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act actual results, levels of activity, perfor
Slide 3: We are a clinical-stage biotech company
We are a clinical-stage Programs 20+ 2 2 biotech company We are advancing an internal Internal Molecules in Molecules pipeline of programs. program IND-enabling in the clinic1 starts activities focused on developing Partnerships* 100+ 40+ 16 novel antibody Corporate Overview We form strategic partne
Slide 4: Our platform was built through 10+ years of drug discovery partnerships
100+ 16 Our platform was built partnered-initiated molecules from partnered-led through 10+ years of therapeutic programs programs have reached the clinic* with downstreams* drug discovery AbbVie partnerships. Corporate Overview Since 2014, we have partnered with some of the industry’s most innovati
Slide 5: Strategy: use our competitive advantage in antibody drug creation
STRATEGY Use our competitive Discovery for GPCR and ion channel targets advantage in antibody drug creation to build Corporate Overview Novel modalities, including multi-specifics and ADCs a pipeline of differentiated assets. Indication agnostic COPYRIGHT © ABCELLERA 5
Slide 6: Internal Pipeline & Programs
INTERNAL PIPELINE & PROGRAMS Two programs in the clinic, two programs in IND-enabling activities, and 20+ programs in discovery. MOLECULE TARGET THERAPEUTIC AREA STAGE Discovery IND-Enabling Phase 1 Phase 2 Phase 3 ABCL635 Corporate Overview NK3R Endocrinology & Women’s Health ABCL575 OX40L Immunolo
Slide 7: Full Year 2025 Recap
FULL YEAR 2025 RECAP Clinical trials on track, completed platform investments, and started activities at clinical manufacturing site. Corporate Overview Completed platform ABCL635 Phase 1/2 investments by the first Nominated clinical trial initiated (June 2025) two additional half of the year ~$680M
Slide 8: 2026 Priorities
2026 PRIORITIES Advance pipeline to key data readouts for ABCL635 and ABCL575, and set up for additional three INDs in 2027. Corporate Overview ABCL635 Phase 1 clinical ABCL688 progressing through trials topline readout in H2 2026 IND-enabling studies Nominate at least 1 additional development candi
Slide 9: Two readouts in 2026 & potential for multiple catalysts in 2027
Two readouts in 2026 & potential for multiple catalysts in 2027. 2026 2027 Q1 Q2 Q3 Q4 Potential Catalysts in 2027 Readout ABCL635 Phase 1/2 Late stage development of ABCL635 in menopausal VMS Menopausal VMS ABCL635 Initiation of Phase 2 studies of ABCL635 in oncology VMS Corporate Overview VMS in O
Slide 10: Internal Programs
COPYRIGHT © ABCELLERA 10 Corporate Overview Internal Programs
Slide 11: Our Platforms
OUR PLATFORMS 100% human health n = 27 We are unlocking high-value drug targets. 30% oncology & immunology GPCR & Ion Channel Platform Corporate Overview T-cell engagers n=8 ● Clinically validated, membrane-protein targets with large commercial potential that have proven largely intractable 56% usin
Slide 12: ABCL635
COPYRIGHT © ABCELLERA 12 Corporate Overview ABCL635 Internal Programs
Slide 13: Internal Pipeline & Programs: ABCL635
INTERNAL PIPELINE & PROGRAMS ABCL635 is a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes). Target Neurokinin 3 receptor (NK3R) Corporate Overview Target Type G protein-coupled receptor (GPCR) Indication Moderate-to-severe vasomotor symptoms (VMS) as
Slide 14: ABCL635 Phase 1/2 clinical trial with readout anticipated in Q3 2026
ABCL635 In Phase 2 clinical trial with readout anticipated NK3R Antagonist in Q3 2026. Science Commercial Opportunity Differentiation Development Path Corporate Overview ● NK3R is a GPCR involved in ● Approximately 6 million ● Potential for: ● Well-established clinical endocrine homeostasis and wome
Slide 15: ABCL635 Commercial Opportunity
ABCL635 Commercial Opportunity VMS are highly prevalent, significantly impact health and well-being, and are the most common reason for seeking treatment for menopause. Corporate Overview VMS are a significant burden Millions of women seek treatment VMS are the most common symptoms of Approximately 40
Slide 16: ABCL635 Commercial Opportunity
ABCL635 Commercial Opportunity Despite effective treatments, there remains a large unmet need for many women suffering from VMS. Corporate Overview Menopause Hormone Therapy (MHT) is an effective treatment ~12% of women are ~8% of women for VMS, and the current contraindicated.1 discontinue MHT with
Slide 17: ABCL635 Science
ABCL635 Science NK3R antagonists are effective, non-hormonal options for VMS. Pre-Menopause Corporate Overview COPYRIGHT © ABCELLERA 17
Slide 18: ABCL635 Science
ABCL635 Science NK3R antagonists are effective, non-hormonal options for VMS. Menopause Corporate Overview COPYRIGHT © ABCELLERA 18
Slide 19: ABCL635 Science
ABCL635 Science NK3R antagonists are effective, non-hormonal options for VMS. Treatment Corporate Overview COPYRIGHT © ABCELLERA 19 Proposed mechanism of action for ABCL635 based on AbCellera nonclinical data and published literature.
Slide 20: ABCL635 Differentiation
ABCL635 Differentiation Recently approved NK3R therapies are building the market. Fezolinetant (Veozah®) by Astellas Elinzanetant (LynkuetTM) by Bayer Small molecule NK3R antagonist Small molecule NK3R and NK1R antagonist Corporate Overview Stage Stage Approved by US FDA on May 12, 2023 Approved by
Slide 21: ABCL635 Differentiation
ABCL635 Differentiation ABCL635 is designed to offer an improved treatment option for women with moderate-to-severe VMS due to menopause. An antibody-based therapeutic may provide several benefits over current non-hormonal treatments: Corporate Overview Enhanced efficacy Reduced toxicities & side-effec
Slide 22: ABCL575
COPYRIGHT © ABCELLERA 22 Corporate Overview ABCL575 Internal Programs
Slide 23: Internal Pipeline & Programs: ABCL575
INTERNAL PIPELINE & PROGRAMS ABCL575 is a potential best-in-class antibody for the treatment atopic dermatitis. Target Corporate Overview OX40 Ligand (OX40L) Indication Atopic Dermatitis (AD) Therapeutic Area Immunology & Inflammation Status Phase 1 COPYRIGHT © ABCELLERA 23
Slide 24: ABCL575 Phase 1 clinical study readout anticipated in mid 2026
INTERNAL PIPELINE & PROGRAMS ABCL575 Readout of Phase 1 clinical study OX40L Antagonist anticipated in mid 2026 Science Commercial Opportunity Differentiation Development Path Corporate Overview ● OX40L mechanism of action • Atopic dermatitis is an ● Competitive space with ● Well-established clinica
Slide 25: ABCL575 Science
ABCL575 Science ABCL575 targets multiple immune pathways. Atopic Dermatitis Corporate Overview COPYRIGHT © ABCELLERA 25
Slide 26: ABCL575 Science
ABCL575 Science ABCL575 targets multiple immune pathways. Treatment Corporate Overview COPYRIGHT © ABCELLERA 26 Proposed mechanism of action for ABCL575 based on AbCellera nonclinical data and published literature.
Slide 27: Royalty Portfolio & Partnered Programs
Corporate Overview Royalty Portfolio & Partnered Programs COPYRIGHT © ABCELLERA 27
Slide 28: Our Partner Portfolio
OUR PARTNER PORTFOLIO 91% human health: target antigen known n = 87 We built industry- 9% animal leading capabilities health n=9 through partnerships with the top-tier 21% 17% Corporate Overview neurology immunology & inflammation of biotech and pharma partners. 47% 6% 5% oncology infectious ophthal-
Slide 29: Partnerships have built a large portfolio of royalties in future antibody medicines
Partnerships have built a large portfolio of royalties in future antibody medicines. Cumulative # of Cumulative # of PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC Corporate Overview WITH DOWNSTREAMS Partner-led AbCellera-led The value of this portfolio will mature over time as our partner
Slide 30: Partner-initiated programs continue to progress towards the clinic
Partner-initiated programs continue to progress towards the clinic. Cumulative # of PARTNER-INITIATED PROGRAMS WITH DOWNSTREAM PARTICIPATION* 6 Not Expected to Progress AbCellera Leading or Co-Leading Work 14 In Progress Corporate Overview 4 Clinical Development 5 Preclinical Development 37 Understo
Slide 31: A cumulative total of molecules have reached the clinic
A cumulative total of 16 molecules have reached the clinic. MOLECULE MOST ADVANCED STAGE THERAPEUTIC AREA(S) PARTNER PROGRAM TYPE bamlanivimab (LY-CoV555) Marketed, Emergency Use Authorization (EUA)* • infectious disease: COVID-19 AbCellera-initiated, partner-led bebtelovimab (LY-CoV1404) Marketed,
Slide 32: Thank You
COPYRIGHT © ABCELLERA 32 Corporate Overview THANK YOU